Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CNOT2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CNOT2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CNOT2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CNOT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CNOT2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CNOT2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CNOT2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CNOT2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CNOT2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CNOT2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064026 | Liver | NAFLD | mRNA catabolic process | 56/1882 | 232/18723 | 3.49e-10 | 9.27e-08 | 56 |
GO:00346556 | Liver | NAFLD | nucleobase-containing compound catabolic process | 80/1882 | 407/18723 | 3.07e-09 | 4.61e-07 | 80 |
GO:00064016 | Liver | NAFLD | RNA catabolic process | 61/1882 | 278/18723 | 3.26e-09 | 4.76e-07 | 61 |
GO:00610136 | Liver | NAFLD | regulation of mRNA catabolic process | 42/1882 | 166/18723 | 1.27e-08 | 1.65e-06 | 42 |
GO:00713836 | Liver | NAFLD | cellular response to steroid hormone stimulus | 48/1882 | 204/18723 | 1.50e-08 | 1.83e-06 | 48 |
GO:00064177 | Liver | NAFLD | regulation of translation | 85/1882 | 468/18723 | 4.58e-08 | 4.54e-06 | 85 |
GO:00434886 | Liver | NAFLD | regulation of mRNA stability | 39/1882 | 158/18723 | 8.49e-08 | 7.09e-06 | 39 |
GO:00305226 | Liver | NAFLD | intracellular receptor signaling pathway | 55/1882 | 265/18723 | 1.39e-07 | 1.03e-05 | 55 |
GO:00434876 | Liver | NAFLD | regulation of RNA stability | 40/1882 | 170/18723 | 2.32e-07 | 1.58e-05 | 40 |
GO:00610144 | Liver | NAFLD | positive regulation of mRNA catabolic process | 24/1882 | 87/18723 | 3.17e-06 | 1.27e-04 | 24 |
GO:00611574 | Liver | NAFLD | mRNA destabilization | 23/1882 | 84/18723 | 5.79e-06 | 2.05e-04 | 23 |
GO:00097556 | Liver | NAFLD | hormone-mediated signaling pathway | 39/1882 | 190/18723 | 1.15e-05 | 3.58e-04 | 39 |
GO:19033134 | Liver | NAFLD | positive regulation of mRNA metabolic process | 28/1882 | 118/18723 | 1.21e-05 | 3.70e-04 | 28 |
GO:00507794 | Liver | NAFLD | RNA destabilization | 23/1882 | 88/18723 | 1.34e-05 | 3.97e-04 | 23 |
GO:00009564 | Liver | NAFLD | nuclear-transcribed mRNA catabolic process | 26/1882 | 112/18723 | 3.68e-05 | 9.23e-04 | 26 |
GO:00434016 | Liver | NAFLD | steroid hormone mediated signaling pathway | 28/1882 | 136/18723 | 1.78e-04 | 3.14e-03 | 28 |
GO:00171483 | Liver | NAFLD | negative regulation of translation | 43/1882 | 245/18723 | 2.05e-04 | 3.56e-03 | 43 |
GO:00342493 | Liver | NAFLD | negative regulation of cellular amide metabolic process | 46/1882 | 273/18723 | 3.27e-04 | 5.04e-03 | 46 |
GO:00002894 | Liver | NAFLD | nuclear-transcribed mRNA poly(A) tail shortening | 10/1882 | 29/18723 | 3.42e-04 | 5.22e-03 | 10 |
GO:00305185 | Liver | NAFLD | intracellular steroid hormone receptor signaling pathway | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CNOT2 | SNV | Missense_Mutation | | c.420N>T | p.Met140Ile | p.M140I | Q9NZN8 | protein_coding | tolerated(0.38) | benign(0.003) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
CNOT2 | SNV | Missense_Mutation | | c.77N>T | p.Arg26Ile | p.R26I | Q9NZN8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.979) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CNOT2 | SNV | Missense_Mutation | novel | c.1620N>G | p.Phe540Leu | p.F540L | Q9NZN8 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.899) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CNOT2 | SNV | Missense_Mutation | novel | c.118N>A | p.Glu40Lys | p.E40K | Q9NZN8 | protein_coding | deleterious_low_confidence(0.04) | benign(0.079) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CNOT2 | SNV | Missense_Mutation | novel | c.608N>A | p.Gly203Glu | p.G203E | Q9NZN8 | protein_coding | deleterious(0.03) | benign(0.081) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
CNOT2 | SNV | Missense_Mutation | rs756678475 | c.1055C>T | p.Thr352Met | p.T352M | Q9NZN8 | protein_coding | tolerated(0.06) | possibly_damaging(0.891) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CNOT2 | SNV | Missense_Mutation | novel | c.683N>T | p.Ser228Leu | p.S228L | Q9NZN8 | protein_coding | deleterious(0) | benign(0.305) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CNOT2 | SNV | Missense_Mutation | novel | c.746T>G | p.Ile249Arg | p.I249R | Q9NZN8 | protein_coding | tolerated(0.35) | benign(0.013) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CNOT2 | SNV | Missense_Mutation | | c.766N>T | p.Ala256Ser | p.A256S | Q9NZN8 | protein_coding | tolerated(0.24) | benign(0.005) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CNOT2 | SNV | Missense_Mutation | rs750913052 | c.368C>T | p.Thr123Met | p.T123M | Q9NZN8 | protein_coding | tolerated_low_confidence(0.15) | possibly_damaging(0.459) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |